The earnings call reflected a strong performance in revenue growth and global expansion of KymTrak, as well as promising advancements in clinical trials and a solid financial position. However, challenges in European reimbursement and uncertainties in HIV treatment results were noted. The overall sentiment is predominantly positive due to significant achievements outweighing the challenges.

Company Guidance -

Q3 2025

During the Immunocore Holdings plc conference call for the fourth quarter and full year 2024, the company provided various metrics highlighting its performance and future guidance. KymTrak, a key product, generated $310 million in net revenues for the year, reflecting a 30% year-on-year growth, with $84.1 million in net revenues in Q4, marking a 5% increase from the prior quarter. The U.S. market saw significant growth, contributing $206 million, a 34% increase year-on-year. Immunocore's clinical pipeline progressed with three ongoing phase three trials, including TEBIAM and ATOM for melanoma, and the initiation of two phase one trials. The company also advanced into autoimmune diseases, targeting type 1 diabetes and atopic dermatitis. For 2025, Immunocore expects incremental growth in KymTrak led by U.S. market penetration and new international launches, with R&D expenses projected to increase as they advance their pipeline. Immunocore reported a strong cash position of $820 million, supporting its continued focus on delivering transformative medicines.

KymTrak Revenue Growth

KymTrak achieved a 5% growth in Q4 versus Q3, with a 30% year-on-year revenue growth, culminating in a total of $310 million in revenue for the year 2024.

Global Expansion of KymTrak

KymTrak was launched in fourteen new countries, bringing the total to thirty-nine countries. It has over 80% market share of HLA-201 positive patients in major markets.

Strong Financial Position

Immunocore Holdings reported $820 million in cash and marketable securities at the end of 2024 after repaying a $50 million loan.

Advancement of Clinical Trials

Progress was made in three ongoing phase three trials, including TEBIAM and ATOM, and a new trial, Plizumel, was initiated. Two phase one trials with novel molecules were also started.

Promising Pipeline in Infectious Diseases and Autoimmune

Completion of the HBV single ascending dose trial and progress in HIV trials, with advancements in autoimmune candidates targeting type 1 diabetes and atopic dermatitis.

Immunocore Holdings (IMCR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IMCR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.25 / -	0.17	―	―	―
Aug 07, 2025	2025 (Q2)	-0.14 / -0.20	-0.23	13.04% (+0.03)
May 07, 2025	2025 (Q1)	-0.38 / 0.10	-0.49	120.41% (+0.59)	―	―
Feb 26, 2025	2024 (Q4)	-0.23 / -0.47	-0.4	-17.50% (-0.07)
Nov 06, 2024	2024 (Q3)	-0.34 / 0.17	0.049	246.94% (+0.12)	―	―
Aug 08, 2024	2024 (Q2)	-0.48 / -0.23	-0.369	37.67% (+0.14)
May 08, 2024	2024 (Q1)	-0.37 / -0.49	-0.43	-13.95% (-0.06)	―	―
Feb 28, 2024	2023 (Q4)	-0.25 / -0.40	-0.63	36.51% (+0.23)
Nov 07, 2023	2023 (Q3)	-0.35 / 0.05	0.137	-64.23% (-0.09)	―	―
Aug 10, 2023	2023 (Q2)	-0.39 / -0.37	-0.172	-114.53% (-0.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IMCR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$32.10	$31.93	-0.53%
May 07, 2025	$28.06	$29.92	+6.63%
Feb 26, 2025	$29.21	$30.77	+5.34%
Nov 06, 2024	$32.99	$33.51	+1.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Immunocore Holdings (IMCR) report earnings?

Immunocore Holdings (IMCR) is schdueled to report earning on Nov 05, 2025, Before Open (Confirmed).

What is Immunocore Holdings (IMCR) earnings time?

Immunocore Holdings (IMCR) earnings time is at Nov 05, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IMCR EPS forecast?

IMCR EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing